Thierry E Appelboom
Hopital Erasme Brussels, Belgium. | University of Brussels, Belgium | Hopital Erasme, Brussels, Belgium. | Department of Rheumatology, Erasme Hospital, University of Brussels, ...
KOL Resume for Thierry E Appelboom
Hopital Erasme Brussels, Belgium.
University of Brussels, Belgium
Hopital Erasme, Brussels, Belgium.
Department of Rheumatology, Erasme Hospital, University of Brussels, 808 Route de Lennik, 1070, Brussels, Belgium
Service de rhumatologie, hôpital Erasme, université Libre de Bruxelles, Bruxelles, Belgique
Division of Rheumatology and Physical Medicine, Hôpital Erasme, Université libre de Bruxelles, Brussels, Belgium
Division of Rheumatology and Physical Medicine, Hôpital Erasme, Université libre de Bruxelles, 808, Route de Lennik, 1070, Brussels, Belgium
Erasmus Hospital, University of Brussels, Belgium.
Erasme University Hospital, B 1070 Brussels, Belgium
Erasmus University Hospital, University of Brussels, 808 route de Lennik, B-1070 Brussels, Belgium.
Division of Rheumatology, Université Libre de Bruxelles – Hôpital Erasme, Brussels, Belgium, Belgium
Erasme University Hospital
Department of Rheumatology, Erasmus University Hospital of Brussels, Belgium.
Division of Rheumatology, Erasme University Hospital, Faculty of Medicine, Université Libre de Bruxelles, Brussels, Belgium
Hôpital Erasme, Department of Rheumatology, Université Libre de Bruxelles, 808 route de Lennik, B-1070, Brussels, Belgium
Hopital Erasme; Brussels, Belgium
From the Dept of Rheumatology, Erasmus Hospital, Free University of Brussels, Belgium
From the Division of Rheumatology, Erasmus University Hospital, University of Brussels, Belgium
Chief Division of Rheumatology, Erasmus University Hospital, University of Brussels, Brussels, Belgium
Sleep Laboratory, Department of Psychiatry, Rheumatology Unit, Psychiatric Consultant, Erasme Hospital, Serolab, Lausanne, Switzerland;, IRIBHN, Brussels Free University, Brussels, Belgium
Division of Rheumatology, Erasmus Hospital, 808, route de Lennik, B-1070, Brussels
Division of Rheumatology, Erasmus Hospital, University of Brussels, Brussels, Belgium
Service de Rhumatologie, Hǒpital Erasme, School of Medicine, University of Brussels, Belgium
Unit of Magnetic Resonance, School of Medicine, University of Brussels, Brussels, Belgium
Division of Rheumatology, Erasmus Hospital, University of Brussels
Division of Rheumatology, Erasmus University Hospital, University of Brussels, Belgium
Division of Rheumatology, Erasmus University Hospital and Center for the Preservation and the Study of Medical Heritage, University of Brussels, Brussels, Belgium
Erasmus University Hospital—University of Brussels 808, Route de Lennik B-1070, Brussels, Belgium
Division of Rheumatology, Erasme University Hospital, Brussels, Belgium, and Metropolitan General Hospital, San Antonio, Tex., USA
Department of Immunology and Hematology, Erasme Hospital, Universite Libre de Bruxelles, 1070, Brussels, Belgium
Service et Laboratoire de Rhumatologie, Hôpital Erasme, Université Libre de Bruxelles, 808 Route de Lennik, B-1070, Bruxelles, Belgium
Fondation Robert Debré, Brussels, Belgium
Cliniques Universitaires de Bruxelles, Hôpital Erasme, Université Libre de Bruxelles, Bruxelles Belgium
Departments of Immunology and Rheumatology, Saint-Pierre University Hospital, Brussels, Belgium
Departments of Rheumatology and Immunology, Hôpital Universitaire Saint-Pierre, UniversitéLibre de Bruxelles, 1000 Brussels, Belgium
Thierry E Appelboom: Influence Statistics
|treatment comorbidity polymedication||#1|
|lifes broad range||#1|
|fresh serum variations||#1|
|c5a activation products||#1|
|presented features sle||#1|
|mononuclear cells hagg||#1|
|publication arthritis acquired||#1|
|flexofytol painful osteoarthritis||#1|
|serumtreated zymosan serum||#1|
|painful hip radiological||#1|
|il1 activity measurable||#1|
|fibroblastic tissue evidence||#1|
|formal written accounts||#1|
|hagg mononuclear cells||#1|
|neck diffuse low||#1|
|zymosan smaller quantities||#1|
|activation products pmn||#1|
|signal core biopsy||#1|
|polymorphonuclear cell adherence||#1|
|hagg stimulation fluorography||#1|
|idiopathic osteonecrosis core||#1|
|trabecular bone necrosis||#1|
|difference raynaud phenomenon||#1|
|ancient numerous examples||#1|
|flexofytol quality life||#1|
|acquired 16th century||#1|
Open the FULL List in Excel
Prominent publications by Thierry E Appelboom
Costimulatory blockade in patients with rheumatoid arthritis: A pilot, dose‐finding, double‐blind, placebo‐controlled clinical trial evaluating CTLA‐4Ig and LEA29Y eighty‐five days after the first inf
[ PUBLICATION ]
OBJECTIVE: T cells are involved in the pathogenesis of rheumatoid arthritis (RA). In animal models of autoimmune diseases, blockade of costimulatory molecules on antigen-presenting cells has been demonstrated to be effective in preventing or treating this disease by preventing T cell activation. To date, the effect of costimulatory blockade in patients with RA is unknown. The goal of this multicenter, multinational study was to determine the safety and preliminary efficacy of ...
|Known for Costimulatory Blockade | Rheumatoid Arthritis | Autoimmune Diseases | Cell Activation | Animal Models|
Which spinal lesions are associated with new bone formation in patients with ankylosing spondylitis treated with anti-TNF agents? A long-term observational study using MRI and conventional radiography
[ PUBLICATION ]
OBJECTIVE: To study the relationship of spinal inflammation and fatty degeneration (FD) as detected by MRI and new bone formation seen on conventional radiographs (CRs) in ankylosing spondylitis (AS).
METHODS: CRs at baseline, 2 years and 5 years and spinal MRIs at baseline and 2 years of 73 AS patients treated with infliximab in European AS Infliximab Cohort were available. Relative risks (RR) were calculated with a general linear model after adjustment for within-patient ...
|Known for New Bone Formation | 2 Years | Ankylosing Spondylitis | Inflammation Baseline | Spinal Lesions|
Fluoride Salts are no Better at Preventing New Vertebral Fractures than Calcium-Vitamin D in Postmenopausal Osteoporosis: The FAVOStudy
[ PUBLICATION ]
Abstract. Although fluoride salts have been shown to be capable of linearly increasing spinal bone mineral density (BMD) in postmenopausal osteoporosis, the effects of this gain in density on the vertebral fracture rate remain controversial. We conducted a 2-year multicenter, prospective, randomized, double-masked clinical trial in 354 osteoporotic women with vertebral fractures (mean age 65.7 years). They received either fluoride (208 patients), given as sodium fluoride (50 mg/day) or ...
|Known for Postmenopausal Osteoporosis | Vertebral Fractures | Fluoride Salts | 2 Years | Density Calcium|
Antiinflammatory properties of mycophenolate mofetil in murine endotoxemia: inhibition of TNF-α and upregulation of IL-10 release
[ PUBLICATION ]
Mycophenolate mofetil (MMF) is a new immunosuppressive agent currently used in organ transplantation and under evaluation in immune-mediated inflammatory disorders such as rheumatoid arthritis. Although MMF was shown to inhibit purine nucleotide synthesis in lymphocytes, it is still unclear whether it might also exert direct antiinflammatory actions in vivo. To address this question, we evaluated the effects of MMF administration on the responses of mice to a single challenge with ...
|Known for Mycophenolate Mofetil | Murine Endotoxemia | Antiinflammatory Properties | Inbred Balb Mice | Nitric Oxide|
Symptoms modifying effect of avocado/soybean unsaponifiables (ASU) in knee osteoarthritis
[ PUBLICATION ]
OBJECTIVES: We compare the symptomatic effects of 300 or 600mg daily of ASU in patients with knee osteoarthritis.
METHODS: A multicenter, double blind, study comparing a daily intake of 300mg or 600mg of ASU and placebo. The study lasted 3 months and involved patients of both genders, aged 45 to 80 years and presenting with femoro-tibial knee osteoarthritis. The primary endpoint was NSAIDs and analgesics intake between D30 and D90.
RESULTS: All efficacy parameters were significantly ...
|Known for Asu Placebo | Knee Osteoarthritis | Daily Intake | Soybean Unsaponifiables | Symptomatic Effects|
Prolactin Up-Regulates Cathepsin B and D Expression in Minor Salivary Glands of Patients with Sjögren's Syndrome
[ PUBLICATION ]
Various proteases are expressed in the minor salivary glands (MSG) of patients with Sjögren's syndrome (SS), and as we have already shown, prolactin is neosynthesized in the acinar cells of patients with SS. The present study aims to characterize the influence of PRL on the expression of cathepsin B and D in the MSG of patients with SS. Cathepsin B and D expression was investigated immunohistochemically in MSG of 30 patients with SS and 15 healthy volunteers. The presence of cathepsin B ...
|Known for Salivary Glands | Expression Cathepsin | Sjögrens Syndrome | Prolactin Prl | Patients Sjögren|
OBJECTIVE: Tumor necrosis factor alpha (TNFalpha) is a proinflammatory cytokine involved in the pathogenesis of Sjögren's syndrome (SS), and blockade of TNFalpha may reduce the activity of the disease. The purpose of this study was to evaluate the safety and potential efficacy of infliximab, a chimeric human-mouse anti-TNFalpha monoclonal antibody, in patients with active primary SS.
METHODS: This was a single-center, open-label pilot study. Sixteen patients with active primary SS ...
|Known for Infliximab Patients | Primary Sjögren | Salivary Flow | Clinical Benefit | Dry Eyes|
Comparison of the onset and intensity of action of intramuscular meloxicam and oral meloxicam in patients in acute sciatica
[ PUBLICATION ]
In this randomized, double-blind, double-dummy trial, 113 patients with acute sciatica were treated with a single 15-mg dose of meloxicam given intramuscularly (n = 54) or orally (n = 59). There was a significant improvement in induced pain (as measured by using the straight-leg-raising test) in both treatment groups at 60 minutes (P < 0.005), and there was a significant difference in favor of the intramuscular formulation in terms of the time to maximum improvement of induced pain (P = ...
|Known for Acute Sciatica | Oral Meloxicam | Intramuscular Formulation | Local Tolerability | 30 Minutes|
Key People For Rheumatoid Arthritis
Thierry E Appelboom:Expert Impact
Concepts for whichThierry E Appelboomhas direct influence:Rheumatoid arthritis, Femoral head, Salivary glands, Hyaluronic acid, Ankylosing spondylitis, Infliximab patients, Magnetic resonance, Postmenopausal osteoporosis.
Thierry E Appelboom:KOL impact
Concepts related to the work of other authors for whichfor which Thierry E Appelboom has influence:Rheumatoid arthritis, Femoral head, Ankylosing spondylitis, Bone marrow, Inosine pranobex, Autoimmune diseases, Sjögren syndrome.
Is this your profile? Claim your profile Copy URL Embed Link to your profile